Companies researching Ocrevus (ocrelizumab)
Ocrevus (ocrelizumab) is a humanized anti‑CD20 monoclonal antibody employed as an immunosuppressive therapy for multiple sclerosis.
35
companies
List of companies that research Ocrevus (ocrelizumab)
This is sourced from job postings — companies only hire for what they actively use or plan to adopt · how we source this →

Employees14kRevenue$2.3BHigher Education
Ocrevus (ocrelizumab)Low confidence
Employees51Revenue$2MHospitals and Health Care
Ocrevus (ocrelizumab)Low confidence
Employees107kRevenue$68BBiotechnology Research
Ocrevus (ocrelizumab)Low confidence
Employees730Hospitals and Health Care
Ocrevus (ocrelizumab)Low confidence
Employees1kHospitals and Health Care
Ocrevus (ocrelizumab)Low confidence
Employees193kRevenue$105BHospitals and Health Care
Ocrevus (ocrelizumab)Low confidence
Employees127Business Consulting and Services
Ocrevus (ocrelizumab)Low confidence
Employees5Medical Practices
Ocrevus (ocrelizumab)Low confidence
Employees210Hospitals and Health Care
Ocrevus (ocrelizumab)Low confidence
Employees21kRevenue$26BBiotechnology Research
Ocrevus (ocrelizumab)Low confidence
Showing top companies out of 35 that research Ocrevus (ocrelizumab). Get the full list on TheirStack.
Frequently asked questions